Avadel Pharmaceuticals (AVDL) is undervalued, with $2B+ sales potential and key catalysts ahead. Read here for more analysis.
Facing weakened pollution targets and threats of federal inaction, Maryland and Virginia may have to become the agreement’s ...
Annualized Recurring Revenue ("ARR") of $849 million Grew 47% year-over-yearRevenue of $250 million Grew 40% year-over-yearRaises Full Year Guidance for Revenue, Earnings Per Share, and Cash Flow BURL ...
Q25 Gross Profit +12% to $114 million; FY 2025 Gross Profit +14% to $446 million 4Q25 Income from Operations +9% to $22 million; Adjusted EBITDA +33% to $33 million FY 2025 Income from Operations +55% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback